bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S3 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Genotypic status of ALK, TP53, MDM2/4, and MYCN in human neuroblastoma cells used for the DIMSCAN cytotoxicity assay.
Supplementary Tables 1-3 from Keap1–Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein
Authors: Chien Ming-Hsien , Lee Wei-Jiunn , Hsieh Feng-Koo , Li Chia-Feng , Cheng Tsu-Yao , Wang Ming-Yang , Chen Jin-Shing , Chow Jyh-Ming , Jan Yi-Hua , Hsiao Michael , Hua Kuo-Tai , Kuo Min-Liang
Published: April 2023

Supplementary Tables 1-3. Supplementary Table 1: Clinicopathologic characteristics of patients with associated expression of Keap1 protein in NSCLC. Supplementary Table 2: Correlation between levels of Keap1 and Nrf2 expression in lung cancer. Supplementary Table 3: Clinicopathologic characteristics of lung tumors with high and low expression of Nrf2 protein.
Supplementary Figure Legends (Figures 1-8) from Keap1–Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein
Authors: Chien Ming-Hsien , Lee Wei-Jiunn , Hsieh Feng-Koo , Li Chia-Feng , Cheng Tsu-Yao , Wang Ming-Yang , Chen Jin-Shing , Chow Jyh-Ming , Jan Yi-Hua , Hsiao Michael , Hua Kuo-Tai , Kuo Min-Liang
Published: April 2023

Supplementary Figure legends (Figures 1-8)
Supplementary Figure and Table Legends from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

Supplementary Figure and Table Legends
Figure S4 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

pALK signalling upon treatment with vehicle, crizotinib, topo/cyclo and crizotinib/ topo/cyclo in NB-SD p53 mutant xenograft with ALK-F1174L mutation.
Supplementary Table 4 from Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Authors: Dalin Martin G. , Desrichard Alexis , Katabi Nora , Makarov Vladimir , Walsh Logan A. , Lee Ken-Wing , Wang Qingguo , Armenia Joshua , West Lyndsay , Dogan Snjezana , Wang Lu , Ramaswami Deepa , Ho Alan L. , Ganly Ian , Solit David B. , Berger Michael F. , Schultz Nikolaus D. , Reis-Filho Jorge S. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S4. All mutations and copy number alterations in cohort 2.
Figure S3 from Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Authors: Krytska Kateryna , Ryles Hannah T. , Sano Renata , Raman Pichai , Infarinato Nicole R. , Hansel Theodore D. , Makena Monish R. , Song Michael M. , Reynolds C. Patrick , Mossé Yael P.
Published: April 2023

P53 functionality in NB-SD, KELLY, and COG-N-297 cells. (A) Cells were treated with either vehicle or 25 uM melphalan (L-PAM) for 16 hours, then collected and run on a western blot gel.
Supplementary Table 1 from Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Authors: Dalin Martin G. , Desrichard Alexis , Katabi Nora , Makarov Vladimir , Walsh Logan A. , Lee Ken-Wing , Wang Qingguo , Armenia Joshua , West Lyndsay , Dogan Snjezana , Wang Lu , Ramaswami Deepa , Ho Alan L. , Ganly Ian , Solit David B. , Berger Michael F. , Schultz Nikolaus D. , Reis-Filho Jorge S. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S1. List of genes and additional intronic regions included in the MSK-IMPACT next-generation sequencing panel.
Table S1 from Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
Authors: Coghill Anna E. , Pfeiffer Ruth M. , Proietti Carla , Hsu Wan-Lun , Chien Yin-Chu , Lekieffre Lea , Krause Lutz , Teng Andy , Pablo Jocelyn , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Liu Zhiwei , Chen Chien-Jen , Middeldorp Jaap , Mulvenna Jason , Bethony Jeff , Hildesheim Allan , Doolan Denise L.
Published: April 2023

Protein and sequence
Supplemental Methods from Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan
Authors: Coghill Anna E. , Pfeiffer Ruth M. , Proietti Carla , Hsu Wan-Lun , Chien Yin-Chu , Lekieffre Lea , Krause Lutz , Teng Andy , Pablo Jocelyn , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Liu Zhiwei , Chen Chien-Jen , Middeldorp Jaap , Mulvenna Jason , Bethony Jeff , Hildesheim Allan , Doolan Denise L.
Published: April 2023

Supplemental Methods
Figure S2.A from The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
Authors: Vena Francesca , Li Causi Eleonora , Rodriguez-Justo Manuel , Goodstal Samantha , Hagemann Thorsten , Hartley John A. , Hochhauser Daniel
Published: April 2023

Figure S2.A. MEK inhibitor AS703988 induces downregulation of RRM1 protein Immunoblotting analysis of RRM1 protein expression
supplementary Data 1-7 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Authors: Frenel Jean Sebastien , Carreira Suzanne , Goodall Jane , Roda Desam , Perez-Lopez Raquel , Tunariu Nina , Riisnaes Ruth , Miranda Susana , Figueiredo Ines , Nava-Rodrigues Daniel , Smith Alan , Leux Christophe , Garcia-Murillas Isaac , Ferraldeschi Roberta , Lorente David , Mateo Joaquin , Ong Michael , Yap Timothy A. , Banerji Udai , Gasi Tandefelt Delila , Turner Nick , Attard Gerhardt , de Bono Johann S.
Published: April 2023

Supplementary Data 1: Primers and probes for ddPCR assay Supplementary Data 2: Consort Diagram Supplementary Data 3: List of drugs Supplementary Data 4: Cross validation of PGM sequencing assay with ddPCR Supplementary Data 5: To test intra-run assay performance, 3 different libraries were prepared using the same plasma cfDNA from a single patient Supplementary Data 6: See figure 6 below. Supplementary Data 7: Time to progression for patients having a 30% decrease in plasma mutation AF, following targeted drug administration, and association with time to progression by RECIST evaluation.
Supplementary Figures 1-3 from Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
Authors: Karnak David , Engelke Carl G. , Parsels Leslie A. , Kausar Tasneem , Wei Dongping , Robertson Jordan R. , Marsh Katherine B. , Davis Mary A. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Morgan Meredith A.
Published: April 2023

Supplementary Figure 1. The effects of AZD1775 and olaparib on the radiation-induced G2 checkpoint; S2: Sub-G1 DNA content following AZD1775, olaparib, and radiation treatments; S3: Weight loss associated with combined treatment with AZD1775, olaparib, and radiation.
Supplementary Table 5 from Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients
Authors: Parra Edwin R. , Behrens Carmen , Rodriguez-Canales Jaime , Lin Heather , Mino Barbara , Blando Jorge , Zhang Jianjun , Gibbons Don L. , Heymach John V. , Sepesi Boris , Swisher Stephen G. , Weissferdt Annikka , Kalhor Neda , Izzo Julie , Kadara Humam , Moran Cesar , Lee Jack J. , Wistuba Ignacio I.
Published: April 2023

Correlation between median density by mm2 of TAICs expressing immune markers and clinicopathological features in lung ADC specimens.
Supplementary Figure 5. p70S6 kinase signaling promotes prostate cancer perineural invasion. from RET Signaling in Prostate Cancer
Authors: Ban Kechen , Feng Shu , Shao Longjiang , Ittmann Michael
Published: April 2023

Knockdown of p70S6 kinase with two different siRNAs results in decreased perieneural invasion. A LNCaP perineural invasion B.22RV1 perineural invasion. C LNCaP perineural invasion, second siRNA D .22RV1 perineural invasion, second siRNA The p values for t-tests are as indicated.
Supplementary table 2 from Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
Authors: Yakirevich Evgeny , Resnick Murray B. , Mangray Shamlal , Wheeler Michael , Jackson Cynthia L. , Lombardo Kara A. , Lee Jeeyun , Kim Kyoung-Mee , Gill Anthony J. , Wang Kai , Gowen Kyle , Sun James , Miller Vincent A. , Stephens Philip J. , Ali Siraj M. , Ross Jeffrey S. , Safran Howard
Published: April 2023

ALK genomic alterations revealed by comprehensive genomic profiling in clinical cases of colorectal carcinoma
Figure S7 from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Limiting Dilution Assay and stem cell markers staining
Figure S4 from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Metabolism of primary cultures in presence of Galactose
Figure S2 from Efficient Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity
Authors: Oizel Kristell , Chauvin Cynthia , Oliver Lisa , Gratas Catherine , Geraldo Fanny , Jarry Ulrich , Scotet Emmanuel , Rabe Marion , Alves-Guerra Marie-Clotilde , Teusan Raluca , Gautier Fabien , Loussouarn Delphine , Compan Vincent , Martinou Jean-Claude , Vallette François M. , Pecqueur Claire
Published: April 2023

Metabolic phenotyping of primary GBM cultures
Supplemental Figure Legends from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Legends for all Supplemental Figures
Supplemental Figure 5 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Neuregulin-1 expression in a panel of HPV(-) and HPV(+) HNSCC cell lines
Figure S6 from KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Authors: Lal Neeraj , White Brian S. , Goussous Ghaleb , Pickles Oliver , Mason Mike J. , Beggs Andrew D. , Taniere Philippe , Willcox Benjamin E. , Guinney Justin , Middleton Gary W.
Published: April 2023

KRAS mutation is associated with reduced expression of STAT1 and CXCL10.
Supplemental Figure 4 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Knockdown of EGFR and HER2 does not completely block the phosphorylation of HER3 in HPV(+) cell lines
Figure S5 from KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Authors: Lal Neeraj , White Brian S. , Goussous Ghaleb , Pickles Oliver , Mason Mike J. , Beggs Andrew D. , Taniere Philippe , Willcox Benjamin E. , Guinney Justin , Middleton Gary W.
Published: April 2023

Supp Fig 5: CIRC is significantly correlated with all immune cell subpopulations. Pairwise correlations of CIRC and immune cell signatures in (A) TCGA and (B) KFSYSCC data sets.
Supplemental Figure 2 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

Transient knockdown of E6 and E7 increases apoptosis without abrogating MAPK or Src Family Kinase signaling
Figure S3 from KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer
Authors: Lal Neeraj , White Brian S. , Goussous Ghaleb , Pickles Oliver , Mason Mike J. , Beggs Andrew D. , Taniere Philippe , Willcox Benjamin E. , Guinney Justin , Middleton Gary W.
Published: April 2023

CIRC expression is reduced in KRAS mutant CRC.
Supplemental Figure 1 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Authors: Brand Toni M. , Hartmann Stefan , Bhola Neil E. , Peyser Noah D. , Li Hua , Zeng Yan , Isaacson Wechsler Erin , Ranall Max V. , Bandyopadhyay Sourav , Duvvuri Umamaheswar , LaVallee Theresa M. , Jordan Richard C.K. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

HPV(+) HNSCC cell lines express high levels of HER3
Supporting Information from NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability
Authors: Palanichamy Kamalakannan , Kanji Suman , Gordon Nicolaus , Thirumoorthy Krishnan , Jacob John R. , Litzenberg Kevin T. , Patel Disha , Chakravarti Arnab
Published: April 2023

Supplemental Figure S1. NNMT expression levels in sub-types of brain tumors. Data collected from the REMBRANDT database shows the NNMT transcript expression levels in different sub-types of glioma. Supplemental Figure S2. Alteration frequency of NNMT in 123 TCGA studies from various cancer sub-types. The plot obtained from the cBioPortal shows the relative amount of NNMT alteration in a wide range of cancers (1, 2). Supplemental Figure S3. KM plot for GBM tissue samples with differential NNMT expression. Kaplan-Meier survival curves of GBM patients based on relative expression levels of NNMT. Median survival outcome for GBM with > 2 fold NNMT expression is about 15 months and that for < 2 fold is about 50 months with a log-rank-p-value of 0.0004 (complied from the REMBRANDT database). Supplemental Figure S4. Heat map of statistically significantly upregulated genes in prior glioma cases. The heat map generated from recurrent glioma cases demonstrates that NNMT is one of the upregulated genes in glioma. The location of NNMT is indicated by an arrow. Supplemental Figure S5. Tissue Microarray of GBM and Normal brain tissues. Tissue microarray (TMA) shows higher expression levels of NNMT in GBM when compared to normal brain. The top panel shows the Hematoxycilin and Eosin stained TMA.
Supporting Information from NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability
Authors: Palanichamy Kamalakannan , Kanji Suman , Gordon Nicolaus , Thirumoorthy Krishnan , Jacob John R. , Litzenberg Kevin T. , Patel Disha , Chakravarti Arnab
Published: April 2023

Supporting Figure Legends
Figure S4 from Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma
Authors: Iida Yuuki , Ciechanover Aaron , Marzese Diego M. , Hata Keisuke , Bustos Matias , Ono Shigeshi , Wang Jinhua , Salomon Matthew P. , Tran Kevin , Lam Stella , Hsu Sandy , Nelson Nellie , Kravtsova-Ivantsiv Yelena , Mills Gordon B. , Davies Michael A. , Hoon Dave S.B.
Published: April 2023

Tiff file for supplementary figure S4
Figure S1 from Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma
Authors: Iida Yuuki , Ciechanover Aaron , Marzese Diego M. , Hata Keisuke , Bustos Matias , Ono Shigeshi , Wang Jinhua , Salomon Matthew P. , Tran Kevin , Lam Stella , Hsu Sandy , Nelson Nellie , Kravtsova-Ivantsiv Yelena , Mills Gordon B. , Davies Michael A. , Hoon Dave S.B.
Published: April 2023

TIFF file for supplementary figure S1
Figure S5 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Overview of the results of perfusion experiment #2. High uptake of dual-labeled girentuximab was observed in two foci (*) of tumor thrombus in the renal vein (A, B). The central region of the tumor largely consists of necrosis, with little and inhomogeneous uptake of dual-labeled girentuximab. Histology confirms that the tumor center consists of fibrosis and necrosis (H&E staining detail, C), without CAIX expression (D).
Supplemetary Figure S1-S8 from PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia
Authors: Zhou Jingfeng , Nie Danian , Li Juan , Du Xin , Lu Yuhong , Li Yangqiu , Liu Chang , Dai Wei , Wang Yun , Jin Yanli , Pan Jingxuan
Published: April 2023

Figure S1 - Biological and pharmacological inhibition of EZH2 potently dampens growth of IM-sensitive and -resistant CML cells; Figure S2 - GSK126 induces apoptosis in CML cells in a dose- and time-dependent manner; Figure S3 - GSK126 elicits cytochrome c release and mitochondrial damage; Figure S4 - Administration of GSK126 in CML mice reduces LSCs in spleen nucleated cells from CML mice; Figure S5 - Knockdown of EZH2 reduces in vivo LSCs in CML mice; Figure S6 - Pharmacological and biological inhibition of EZH2 in CML mice has minimal effect on LSCs and progenitor cells in BM and spleen nucleated cells from CML mice; Figure S7 - BCR-ABL is not involved in the EZH2 knockdown-enabled PTEN transcriptional elevation; Figure S8 - Knockdown of PTEN weakens the effect of LSCs reduction mediated by silencing EZH2.
Table S1 from Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition
Authors: Ketola Kirsi , Munuganti Ravi S.N. , Davies Alastair , Nip Ka Mun , Bishop Jennifer L. , Zoubeidi Amina
Published: April 2023

Supplementary Table S1. Summary of ENZ resistant cells' characterization
Supplementary Table 1 from Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations
Authors: Friedman Adam A. , Xia Yun , Trippa Lorenzo , Le Long Phi , Igras Vivien , Frederick Dennie T. , Wargo Jennifer A. , Tanabe Kenneth K. , Lawrence Donald P. , Neuberg Donna S. , Flaherty Keith T. , Fisher David E.
Published: April 2023

Screening results for drug combinations, expressed as percent of control (DMSO-treated) values.
Figure S1 from Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Authors: Li Si , Siriwon Natnaree , Zhang Xiaoyang , Yang Shuai , Jin Tao , He Feng , Kim Yu Jeong , Mac John , Lu Zhengfei , Wang Sijie , Han Xiaolu , Wang Pin
Published: April 2023

(A) The production of anti-PD-1 scFv from CAR19.Î±PD1 T cells (1 Ã- 106) after 24-hour culture with or without Brefeldin A. (B) The expression of anti-PD-1 scFv during the course of CAR19.Î±PD1 T cell expansion. The concentration of secreted scFv was measured at four different time points post T cell transduction, including days 4, 7, 10 and 12. The cell density was maintained around 2-4 Ã- 106 per ml during T cell expansion. (C) Human T cells were activated with anti-CD3/CD28 beads for 48 hours and then cultured in T cell culture medium supplemented with 10 ng/ml of human IL-2 for two weeks. The activated T cells were then stained with either isotype control antibody or anti-PD-1 antibody. (D) The activated human T cells were incubated with 1ml of CAR19.Î±PD1 T cell culture supernatant for 30 min. The T cells was washed once with PBS and then stained with anti-HA antibody.
Supplementary Figures 1-17, Supplementary Tables 1-9 from Tumor Purity as an Underlying Key Factor in Glioma
Authors: Zhang Chuanbao , Cheng Wen , Ren Xiufang , Wang Zheng , Liu Xing , Li Guanzhang , Han Sheng , Jiang Tao , Wu Anhua
Published: April 2023

Figure S1: Morphologic validation of glioma purity in 12 cases from CGGA cohort. Figure S2: The distribution of glioma purity, stromal score and immune score. Figure S3: Distributions of glioma purity attributing to TCGA subtype and genomic aberrations. Figure S4: Survival trends among molecular entities. Figure S5: Patterns of tumor purity in primary and recurrent gliomas. Figure S6: The prognostic value of glioma purity in stratified analysis Figure S7: Prognostic implications of glioma purity in recurrent glioma and secondary GBM. Figure S8: The prognostic value of stromal score. Figure S9: The prognostic value of stromal score in stratified cohorts. Figure S10: The prognostic value of immune score. Figure S11: The prognostic value of immune score in stratified cohorts. Figure S12: A nomogram integrating independent prognostic factors. Figure S13: Associations between glioma purity and somatic mutations and CNAs. Figure S14: Distinct somatic mutation and CNA profiles associated with glioma purity. Figure S15: Biological implications associated with glioma purity. Figure S16: IHC analysis verified that macrophage/microglia and neutrophil adversely correlated with glioma purity. Figure S17: Validation of the prognostic value of macrophages, neutrophils and microglia. Table S1: Clinical and molecular characteristics of patients included in this study. Table S2: The information of recurrent glioma and secondary glioblastoma in CGGA and TCGA-microarray cohorts. Table S3: The distribution features of stromal score, immune score and glioma purity. Table S4: The correlation between purity and other parameters in stratified histopathology and molecular classification Table S5: The prognostic value of recognized factors in gliomas with low purity. Table S6: The prognostic value of recognized factors in gliomas with high-purity. Table S7: Genomic aberrations with different frequency between cases with lower and higher purity. Table S8: Different frequency of pathway mutations between cases with lower and higher purity. Table S9: Correlation between glioma purity and immune cells.
Supplementary Table S1 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Authors: Hahn Noah M. , Bivalacqua Trinity J. , Ross Ashley E. , Netto George J. , Baras Alex , Park Jong Chul , Chapman Carolyn , Masterson Timothy A. , Koch Michael O. , Bihrle Richard , Foster Richard S. , Gardner Thomas A. , Cheng Liang , Jones David R. , McElyea Kyle , Sandusky George E. , Breen Timothy , Liu Ziyue , Albany Costantine , Moore Marietta L. , Loman Rhoda L. , Reed Angela , Turner Scott A. , De Abreu Francine B. , Gallagher Torrey , Tsongalis Gregory J. , Plimack Elizabeth R. , Greenberg Richard E. , Geynisman Daniel M.
Published: April 2023

Supplementary Table S1: All-Grade Toxicity
Supplementary Figure Legend from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Authors: Hahn Noah M. , Bivalacqua Trinity J. , Ross Ashley E. , Netto George J. , Baras Alex , Park Jong Chul , Chapman Carolyn , Masterson Timothy A. , Koch Michael O. , Bihrle Richard , Foster Richard S. , Gardner Thomas A. , Cheng Liang , Jones David R. , McElyea Kyle , Sandusky George E. , Breen Timothy , Liu Ziyue , Albany Costantine , Moore Marietta L. , Loman Rhoda L. , Reed Angela , Turner Scott A. , De Abreu Francine B. , Gallagher Torrey , Tsongalis Gregory J. , Plimack Elizabeth R. , Greenberg Richard E. , Geynisman Daniel M.
Published: April 2023

Supplementary Figure Legends
Supplementary Tables, Materials and Methods from ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer
Authors: Blaj Cristina , Bringmann Agnes , Schmidt Eva Marina , Urbischek Manuela , Lamprecht Sebastian , Fröhlich Thomas , Arnold Georg J. , Krebs Stefan , Blum Helmut , Hermeking Heiko , Jung Andreas , Kirchner Thomas , Horst David
Published: April 2023

Supplementary Tables 1-7 Supplementary Materials and Methods Suppl. Table 1. WNT target gene sets used for GSEA Suppl. Table 2. Gene Expression (real-time RT-PCR) primers used in this study. Primers were selected from the Universal Probe Library (Roche). Suppl. Table 3. Antibodies used for immunoblotting and immunohistochemistry. Suppl. Table 4. Fold change (F.C.) of consistently deregulated genes in three gene expression data sets of colon cancer cells with high vs. low WNT activity, and F.C. in differential expression of these genes in TCGA data in colon cancer vs. normal mucosa. P values are t test results. Suppl. Table 5. Proteome analysis results upon ADNP depletion. Proteins with significant up- or downregulation are listed (P < 0.05; abs. fold change >1.5) Suppl. Table 6. Clinical/pathological data and ADNP expression in colorectal cancer. Suppl. Table 7. Multivariate analysis of cancer specific survival.
Supplement method from Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics
Authors: Yan Yuanqing , Gao Ruli , Trinh Thao L.P. , Grant Maria B.
Published: April 2023

Supplement method for real time RT-PCR in PANC-1 cell line
Supplemental Figure S3 from Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Authors: Berns Katrien , Sonnenblick Amir , Gennissen Annemiek , Brohée Sylvain , Hijmans E. Marielle , Evers Bastiaan , Fumagalli Debora , Desmedt Christine , Loibl Sibylle , Denkert Carsten , Neven Patrick , Guo Wei , Zhang Fan , Knijnenburg Theo A. , Bosse Tjalling , van der Heijden Michiel S. , Hindriksen Sanne , Nijkamp Wouter , Wessels Lodewyk F.A. , Joensuu Heikki , Mills Gordon B. , Beijersbergen Roderick L. , Sotiriou Christos , Bernards René
Published: April 2023

Supplemental Figure S3: ARID1A loss correlates with ANXA1 expression in endometrial cancer
Table S2 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Authors: Seed George , Yuan Wei , Mateo Joaquin , Carreira Suzanne , Bertan Claudia , Lambros Maryou , Boysen Gunther , Ferraldeschi Roberta , Miranda Susana , Figueiredo Ines , Riisnaes Ruth , Crespo Mateus , Rodrigues Daniel Nava , Talevich Eric , Robinson Dan R. , Kunju Lakshmi P. , Wu Yi-Mi , Lonigro Robert , Sandhu Shahneen , Chinnaiyan Arul M. , de Bono Johann S.
Published: April 2023

Sample list and sequencing metrics for samples used in this study.
Table S1 from Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification
Authors: Seed George , Yuan Wei , Mateo Joaquin , Carreira Suzanne , Bertan Claudia , Lambros Maryou , Boysen Gunther , Ferraldeschi Roberta , Miranda Susana , Figueiredo Ines , Riisnaes Ruth , Crespo Mateus , Rodrigues Daniel Nava , Talevich Eric , Robinson Dan R. , Kunju Lakshmi P. , Wu Yi-Mi , Lonigro Robert , Sandhu Shahneen , Chinnaiyan Arul M. , de Bono Johann S.
Published: April 2023

Genomic regions used for the targeted panel sequencing in this study.
Table S3 from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

AKT S473 distribution based on ER expression measured by IHC for 31 lesions included of the discovery set. ER was measured in a binary scale (Panel A) and in continuous scale using the H-Score (Panel B).
Supplementary Material Legend from Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Authors: Pierobon Mariaelena , Ramos Corinne , Wong Shukmei , Hodge K. Alex , Aldrich Jessica , Byron Sara , Anthony Stephen P. , Robert Nicholas J. , Northfelt Donald W. , Jahanzeb Mohammad , Vocila Linda , Wulfkuhle Julia , Gambara Guido , Gallagher Rosa I. , Dunetz Bryant , Hoke Nicholas , Dong Ting , Craig David W. , Cristofanilli Massimo , Leyland-Jones Brian , Liotta Lance A. , O'Shaughnessy Joyce A. , Carpten John D. , Petricoin Emanuel F.
Published: April 2023

Supplementary material legend
Figure S4 from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

HMGA2-FOXL2 pathway regulated cell invasion and metastasis in multiple GC cell lines. A. HMGA2 and FOXL2 were increased and EMT was induced in BGC823 cells with a 24-h exposure to low concentration of ADR. **P<0.01. B. Similar alterations to HMGA2, FOXL2, E-cadherin and Vimentin were found in AGS treated with low concentration of 5-FU for 48h or 72h. **P<0.01. C-D. Ectopic HMGA2 induced the expression of FOXL2 and increased cell migration and invasion of BGC823 (C) and AGS (D) cells. E-F. Knockdown of HMGA2 inhibited FOXL2 and cell motility of MKN28 (E) and MKN45 (F) cells.
Figure S1 from Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase
Authors: Dai Xiaoyang , Yan Juan , Fu Xuhong , Pan Qiuming , Sun Danni , Xu Yuan , Wang Jiang , Nie Litong , Tong Linjiang , Shen Aijun , Zheng Mingyue , Huang Min , Tan Minjia , Liu Hong , Huang Xun , Ding Jian , Geng Meiyu
Published: April 2023

supplementary Figure S1 shows the annotated spectrum of VFQVVESTRPGK (326-337) from heparanase
Figure S1 from HMGA2–FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer
Authors: Dong Jiaqiang , Wang Rui , Ren Gui , Li Xiaowei , Wang Jingbo , Sun Yi , Liang Jie , Nie Yongzhan , Wu Kaichun , Feng Bin , Shang Yulong , Fan Daiming
Published: April 2023

The characteristics of chemo-sensitive and chemo-resistant GC cell lines. A. Tumors derived from distant metastases were more resistant to chemotherapy. A 3-week 5-FU administration treatment was performed when the secondary model was established for 2 weeks and the tumor burden was then analysed. B-C. The protein expression of HMGA2, FOXL2, ITGA2, E2F1 and Rb in chemo-sensitive and chemo-resistant GC cell lines. **P<0.01. D. The mRNA levels of HMGA2, FOXL2, ITGA2, CDC2, CCNE1 and TK1 in chemo-resistant and chemo-sensitive GC cells. **P<0.01.
Supplementary Table S3 from A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Authors: Yam Clinton , Xu Xiaowei , Davies Michael A. , Gimotty Phyllis A. , Morrissette Jennifer J.D. , Tetzlaff Michael T. , Wani Khalida M. , Liu Shujing , Deng Wanleng , Buckley Meghan , Zhao Jianhua , Amaravadi Ravi K. , Haas Naomi B. , Kudchadkar Ragini R. , Pavlick Anna C. , Sosman Jeffrey A. , Tawbi Hussein , Walker Luke , Schuchter Lynn M. , Karakousis Giorgos C. , Gangadhar Tara C.
Published: April 2023

Best response to treatment. A table summarizing the best responses to study treatment in all patients. This table also compares responses in patients who received BRAF/MEK inhibitors prior to study enrollment with patients who did not.
Supplementary Figure 1 from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Authors: Duffy Austin G. , Ma Chi , Ulahannan Susanna V. , Rahma Osama E. , Makarova-Rusher Oxana , Cao Liang , Yu Yunkai , Kleiner David E. , Trepel Jane , Lee Min-Jung , Tomita Yusuke , Steinberg Seth M. , Heller Theo , Turkbey Baris , Choyke Peter L. , Peer Cody J. , Figg William D. , Wood Brad J. , Greten Tim F.
Published: April 2023

Figure
Supplemental Data legends from Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Authors: Duffy Austin G. , Ma Chi , Ulahannan Susanna V. , Rahma Osama E. , Makarova-Rusher Oxana , Cao Liang , Yu Yunkai , Kleiner David E. , Trepel Jane , Lee Min-Jung , Tomita Yusuke , Steinberg Seth M. , Heller Theo , Turkbey Baris , Choyke Peter L. , Peer Cody J. , Figg William D. , Wood Brad J. , Greten Tim F.
Published: April 2023

Supplemental Data legends
Supplementary Table 5 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

RPPA data of human CD8+ TIL (N=5) stimulated with anti-CD3 with or without HVEM-FC
Movie 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Authors: Ritthipichai Krit , Haymaker Cara L. , Martinez Melisa , Aschenbrenner Andrew , Yi Xiaohui , Zhang Minying , Kale Charuta , Vence Luis M. , Roszik Jason , Hailemichael Yared , Overwijk Willem W. , Varadarajan Navin , Nurieva Roza , Radvanyi Laszlo G. , Hwu Patrick , Bernatchez Chantale
Published: April 2023

Movie 1 from Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter
Supplementary Table S1 from FUS–DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma
Authors: Trautmann Marcel , Menzel Jasmin , Bertling Christian , Cyra Magdalene , Isfort Ilka , Steinestel Konrad , Elges Sandra , Grünewald Inga , Altvater Bianca , Rossig Claudia , Fröhling Stefan , Hafner Susanne , Simmet Thomas , Åman Pierre , Wardelmann Eva , Huss Sebastian , Hartmann Wolfgang
Published: April 2023

Clinicopathological characteristics of the included patients with myxoid liposarcoma and semi-quantitative immunohistochemistry results
Figure S2 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S2 shows that down-regulation of SAFB activated NF-κB signaling pathway
Supplementary methods and materials from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Supplementary methods and materials
Supplementary Table S2 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Table S2
Supplementary Table S1 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Characteristics of 110 patients analyzed in this study.
Supplemental Figure 6 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Growth characteristics and HCQ sensitivity of ATG5 and ATG7 knockdown cells.
Supp Fig S4 from MSH2 Loss in Primary Prostate Cancer
Authors: Guedes Liana B. , Antonarakis Emmanuel S. , Schweizer Michael T. , Mirkheshti Nooshin , Almutairi Fawaz , Park Jong Chul , Glavaris Stephanie , Hicks Jessica , Eisenberger Mario A. , De Marzo Angelo M. , Epstein Jonathan I. , Isaacs William B. , Eshleman James R. , Pritchard Colin C. , Lotan Tamara L.
Published: April 2023

MSH2/6 immunostains in a formalin fixed and paraffin embedded primary prostate tumor with single copy MSH2 loss by sequencing. Standard tissue section of tumor with apparent single copy somatic gene inactivation of MSH2 (MSH2 c. 1728del), showing loss of both MSH2 and MSH6 immunostaining, with intact staining in stromal cells and lymphocytes for both markers. All photomicrographs are reduced from 200x.
Supplementary Materials and Methods from Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Authors: Torres-Adorno Angie M. , Lee Jangsoon , Kogawa Takahiro , Ordentlich Peter , Tripathy Debu , Lim Bora , Ueno Naoto T.
Published: April 2023

Supplementary Materials and Methods, including additional summary of the methodologies used.
SupplementaryTables from KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition
Authors: Cho Soo-Jeong , Yoon Changhwan , Lee Jun Ho , Chang Kevin K. , Lin Jian-xian , Kim Young-Ho , Kook Myeong-Cherl , Aksoy Bülent Arman , Park Do Joong , Ashktorab Hassan , Smoot Duane T. , Schultz Nikolaus , Yoon Sam S.
Published: April 2023

Supplementary Tables 1-4
Supplementary Figures from KMT2C Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition
Authors: Cho Soo-Jeong , Yoon Changhwan , Lee Jun Ho , Chang Kevin K. , Lin Jian-xian , Kim Young-Ho , Kook Myeong-Cherl , Aksoy Bülent Arman , Park Do Joong , Ashktorab Hassan , Smoot Duane T. , Schultz Nikolaus , Yoon Sam S.
Published: April 2023

Supplementary Figures S1-S5
Supplementary figures from Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition
Authors: Quispel-Janssen Josine M. , Badhai Jitendra , Schunselaar Laurel , Price Stacey , Brammeld Jonathan , Iorio Francesco , Kolluri Krishna , Garnett Matthew , Berns Anton , Baas Paul , McDermott Ultan , Neefjes Jacques , Alifrangis Constantine
Published: April 2023

Figure S1. A subset MPM cell lines respond to FGFR inhibition. A) AZD4547 at a fixed dose of 500nM and B) BGJ-398 at a fixed dose of 300nM. Figure S2. A subset of pleural fluid derived early passage primary cultures (EPL) respond to FGFR inhibition. Figure S3. BAP1 mutation status does not correlate fully with protein expression. Figure S4. BAP1 null cell lines show increased activity of multiple receptor tyrosine kinases. Figure S5. FGF9 activates FGFR3 and modulates growth and phenotype. Figure S6. Gene expression studies comparing H226 BAP1 C91 vs BAP1 wt construct cell line. Figure S7. xenograft Immunohistochemistry for ki67, Caspase 3 under various experimental conditions. Figure S8. Anchor based combination drug screen in MPM using Pi3 kinase inhibitor as anchor drug.
Supplementary Figure 1 from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Authors: Sabbaghi MohammadA , Gil-Gómez Gabriel , Guardia Cristina , Servitja Sonia , Arpí Oriol , García-Alonso Sara , Menendez Silvia , Arumi-Uria Montserrat , Serrano Laia , Salido Marta , Muntasell Aura , Martínez-García Maria , Zazo Sandra , Chamizo Cristina , González-Alonso Paula , Madoz-Gúrpide Juan , Eroles Pilar , Arribas Joaquin , Tusquets Ignasi , Lluch Ana , Pandiella Atanasio , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Effects of T-DM1 on 750 cyclin B1 (CCNB1) mRNA expression in T751 DM1 sensitive and resistant breast cancer cells.
Supporting information tracked changes from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Authors: Leyland Rebecca , Watkins Amanda , Mulgrew Kathy A. , Holoweckyj Nicholas , Bamber Lisa , Tigue Natalie J. , Offer Emily , Andrews John , Yan Li , Mullins Stefanie , Oberst Michael D. , Coates Ulrichsen Jane , Leinster David A. , McGlinchey Kelly , Young Lesley , Morrow Michelle , Hammond Scott A. , Mallinder Philip , Herath Athula , Leow Ching Ching , Wilkinson Robert W. , Stewart Ross
Published: April 2023

Additional materials and methods and supplementary figure legends with tracked changes
Supporting information from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Authors: Leyland Rebecca , Watkins Amanda , Mulgrew Kathy A. , Holoweckyj Nicholas , Bamber Lisa , Tigue Natalie J. , Offer Emily , Andrews John , Yan Li , Mullins Stefanie , Oberst Michael D. , Coates Ulrichsen Jane , Leinster David A. , McGlinchey Kelly , Young Lesley , Morrow Michelle , Hammond Scott A. , Mallinder Philip , Herath Athula , Leow Ching Ching , Wilkinson Robert W. , Stewart Ross
Published: April 2023

Additional materials and methods and supplementary figure legends.
Supplementary figures from A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist
Authors: Leyland Rebecca , Watkins Amanda , Mulgrew Kathy A. , Holoweckyj Nicholas , Bamber Lisa , Tigue Natalie J. , Offer Emily , Andrews John , Yan Li , Mullins Stefanie , Oberst Michael D. , Coates Ulrichsen Jane , Leinster David A. , McGlinchey Kelly , Young Lesley , Morrow Michelle , Hammond Scott A. , Mallinder Philip , Herath Athula , Leow Ching Ching , Wilkinson Robert W. , Stewart Ross
Published: April 2023

Supplementary figures S1-4
Supplementary Figure from Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer
Authors: Chen Ke , Xiao Haibing , Zeng Jin , Yu Gan , Zhou Hui , Huang Chunhua , Yao Weimin , Xiao Wei , Hu Junhui , Guan Wei , Wu Lily , Huang Jiaoti , Huang Qihong , Xu Hua , Ye Zhangqun
Published: April 2023

Supplementary Figure from Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer
Supplementary Methods, Supplementary Results, Supplementary Table 1, Supplementary Figures 1-8 from The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Authors: Zhang Sen , Anjum Rana , Squillace Rachel , Nadworny Sara , Zhou Tianjun , Keats Jeff , Ning Yaoyu , Wardwell Scott D. , Miller David , Song Youngchul , Eichinger Lindsey , Moran Lauren , Huang Wei-Sheng , Liu Shuangying , Zou Dong , Wang Yihan , Mohemmad Qurish , Jang Hyun Gyung , Ye Emily , Narasimhan Narayana , Wang Frank , Miret Juan , Zhu Xiaotian , Clackson Tim , Dalgarno David , Shakespeare William C. , Rivera Victor M.
Published: April 2023

Supplementary Table 1. Brigatinib in vitro activity (IC50s) in a kinase panel (N=289); Supplementary Figure 1. Chemical structures of brigatinib, crizotinib, ceritinib, and alectinib; Supplementary Figure 2. Brigatinib-mediated inhibition of native or mutant ALK-, ROS1-,FLT3-, and EGFR-driven tumor activity in vitro; Supplementary Figure 3. Cellular and in vivo activity of brigatinib in ROS1 harboring models, compared with crizotinib; Supplementary Figure 4. Comparison of IGF-1R and INSR inhibitory activity of brigatinib with NVP-TAE684; Supplementary Figure 5. Inhibition of ALK phosphorylation in ALK+ cellular models by brigatinib, compared with crizotinib; Supplementary Figure 6. Inhibition of ALK phosphorylation and downstream signaling, and tolerability of brigatinib in vivo, compared with crizotinib; Supplementary Figure 7. TKI activity against parental, and native and mutant EML4-ALK driven Ba/F3 cells; Supplementary Figure 8. TKI antitumor activity against native and mutant EML4-ALK tumors, TKI plasma levels, and tolerability, in vivo.
Supplementary table 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Authors: He Xiao-yan , Tan Zheng-lan , Mou Qin , Liu Fang-jie , Liu Shan , Yu Chao-wen , Zhu Jin , Lv Lin-ya , Zhang Jun , Wang Shan , Bao Li-ming , Peng Bin , Zhao Hui , Zou Lin
Published: April 2023

The correlation of miR-221 expression with clinicopathologic features in NB patients
Supplementary Table 2 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Table listing the top hits of the three databases anlayzed with the DisCoVER method
Supplementary Table 1 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Table listing the genes composing the hNSC G3 signature